ライフサイエンスコーパス: hemoglobin A1c

1 ore and liver stiffness) and correlated with hemoglobin A1C.

2 l MFN1 content was inversely proportional to hemoglobin A1C.

3 oprotein cholesterol, smoking cessation, and hemoglobin A1c.

4 timated insulin resistance, and glycosylated hemoglobin A1c.

5 The primary outcome was most recent level of hemoglobin A1c.

6 better in the RSG group (mean difference in hemoglobin A1c -0.65%, p < 0.0001).

7 biopsies of patients with diabetes mellitus (hemoglobin A1c, 10+/-2%) demonstrated reduced overall ce

8 A1c=6.5 +/- 0.15), and nondiabetic patients (hemoglobin A1c=5.4 +/- 0.12) undergoing coronary artery

9 Diabetic patients (hemoglobin A1c, 6.8 +/- 0.4%) had a higher resting HR (7

10 0.25), controlled type 2 diabetic patients (hemoglobin A1c=6.5 +/- 0.15), and nondiabetic patients (

11 (n = 10; 44 +/- 12 years, 8 female subjects, hemoglobin A1c 7.7 +/- 0.6%).

12 en patients with poorly controlled PDR (mean hemoglobin A1C = 9.2 +/- 2.0%) and 10 control subjects w

13 from uncontrolled type 2 diabetic patients (hemoglobin A1c=9.6 +/- 0.25), controlled type 2 diabetic

14 d as a health care provider diagnosis, serum hemoglobin A1C (A1C) >/=6.5%, or fasting plasma glucose

15 glycemic control determined by preprocedural hemoglobin A1c (A1c) and the incidence of target vessel

16 t each visit for the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, and MMP-9.

17 essure, low-density lipoprotein cholesterol, hemoglobin A1c, albuminuria, glomerular filtration rate,

18 diovascular disease (806 events) and between hemoglobin A1c and all-cause mortality (521 deaths) was

19 Lower hemoglobin A1c and BP and regression to AER<300 mg/d wer

20 amples were used to assess concentrations of hemoglobin A1c and C-reactive protein.

21 In men and women, the relationship between hemoglobin A1c and cardiovascular disease (806 events) a

22 Hemoglobin A1c and cardiovascular disease risk factors w

23 etabolic profiling, including measurement of hemoglobin A1c and lipid levels and carotid ultrasonogra

24 A total of 15,737 patients had an hemoglobin A1c and medical record evaluable for the hist

25 tions included urine culture, measurement of hemoglobin A1c and postvoid residual bladder volume, and

26 re was a graded inverse relationship between Hemoglobin A1c and SVR rate (P = .0482).

27 No clear linear trend between hemoglobin A1c and UTI or AB risk was seen.

28 omocysteine, fibrinogen, C-reactive protein, hemoglobin A1c, and creatinine were measured at baseline

29 type, NAS >/= 5, bilirubin, body mass index, hemoglobin A1C, and dyslipidemia.

30 mass index, diabetes duration, glycosylated hemoglobin A1c, and fasting C-peptide.

31 l assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had sig

32 l assessment of insulin resistance, insulin, hemoglobin A1c, and low high-density lipoprotein had sig

33 ence definitions defined by fasting glucose, hemoglobin A1c, and medication use obtained during an in

34 c characteristics; medications; cholesterol, hemoglobin A1c, and serum creatinine levels; blood press

35 anic blacks, individuals with high levels of hemoglobin A1c, and those with longer duration of diabet

36 ace, follow-up interval, insulin dependence, hemoglobin A1c, and total number of lasers spots.

37 nificantly greater weight loss, reduction in hemoglobin A1c, and use of antidiabetic medications, and

38 liter), C-peptide (in nanomoles per liter), hemoglobin A1c (as a percentage) and insulin dose (U/kg

39 nfidence interval [CI], 0.38-0.44; P<0.001), hemoglobin A1C assessment (odds ratios 0.41; 95% CI, 0.3

40 Measurement of hemoglobin A1c at admission can prospectively identify a

41 Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based

42 d, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent.

43 , 65.5%, 56.6%, and 80.6% met individualized hemoglobin A1c, blood pressure (BP <140/80 mmHg), lipid

44 ciation was independent of diabetes control (hemoglobin A1c, blood pressure, and lipid levels), prese

45 goals, respectively; 26.7% met combined ABC (hemoglobin A1c, BP, and LDL cholesterol) targets, and 21

46 d adults, 77.0%, 57.9%, 36.0%, and 77.9% met hemoglobin A1c, BP, lipid, and nonsmoking goals, respect

47 Tested as continuous variables, glycated hemoglobin A1C, but neither body mass index nor the insu

48 se by 0.69 mmol/L [1.32; 0.07], glycosylated hemoglobin A1C by 0.37% [0.54; 0.20], body weight by 2.5

49 arkers of glycemic control (fasting insulin, hemoglobin A1c, C-peptide, and leptin), lipids (total ch

50 disease, alcohol/drug use, income/education, hemoglobin A1C, C-reactive protein, lactate dehydrogenas

51 h or without metformin had similar levels of hemoglobin A1c, cholesterol, and blood pressure.

52 i-diabetic medications, as well as levels of hemoglobin A1C, cholesterol, hemoglobin, creatinine, and

53 model assessment of insulin resistance, and hemoglobin A1c) compared with fast ethanol metabolizers

54 random glucose level of at least 200 mg/dL, hemoglobin A1c concentration of at least 6.5% of total h

55 randomized trials of interventions to reduce hemoglobin A1c concentrations in persons without diabete

56 disease and total mortality associated with hemoglobin A1c concentrations increased continuously thr

57 Persons with hemoglobin A1c concentrations less than 5% had the lowes

58 gainst statistically significant declines in hemoglobin A1c control.

59 e-1 (sICAM-1), homocysteine, lipoprotein(a), hemoglobin A1c, creatinine, and conventional lipid level

60 Age, albumin/creatinine ratio, hemoglobin A1c, diabetes, hypertension, and lipid-loweri

61 o the lower risk of CVD (28.7%), followed by hemoglobin A1c/diabetes (25.3%), inflammatory/hemostatic

62 re attributed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine and

63 Although mean hemoglobin A1c did not change, the proportion of persons

64 h empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups

65 t size of -0.36 (95% CI, -0.52 to -0.21) for hemoglobin A1c, equivalent to a reduction in hemoglobin

66 Blood samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

67 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin were abstra

68 BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and li

69 icant differences in fasting plasma glucose, hemoglobin A1c, fasting insulin or C-peptide, acute insu

70 Mean hemoglobin A1c for the population was 7.9+/-1.8%.

71 l of low-density lipoprotein cholesterol and hemoglobin A1c (for example, 86% vs. 72% for low-density

72 ized prevalence of total diabetes (using the hemoglobin A1c, FPG, or 2-hour PG definition) was higher

73 e (2-hour PG) level of 200 mg/dL or greater (hemoglobin A1c, FPG, or 2-hour PG definition).

74 lation, the unadjusted prevalence (using the hemoglobin A1c, FPG, or 2-hour PG definitions for diabet

75 sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

76 ted compounds to detect tHb and glycosylated hemoglobin A1c (GHbA1c) in human whole blood without sam

77 The percentage of glycosylated hemoglobin A1c (%GHbA1c) in human whole blood indicates

78 but nonsignificant effects on the change in hemoglobin A1c, glucose, and insulin levels.

79 Insulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes.

80 Diabetes was defined as hemoglobin A1c greater than 6.5% or use of glucose-lower

81 This represented 41.0% of patients with an hemoglobin A1c > 6.5% and 9.3% of all ICU patients.

82 diabetes), and uncontrolled known diabetes (hemoglobin A1c > 6.5%, with documented history of diabet

83 were categorized as having unknown diabetes (hemoglobin A1c > 6.5%, without history of diabetes), no

84 ns with diabetes with poor glycemic control (hemoglobin A1c > 9%) showed a nonstatistically significa

85 00/140/200 mg/dL [5.55/7.77/11.10 mmol/L] or hemoglobin A1C >/= 5.7% [39 mmol/mol]); (2) diagnosis co

86 herapy for >/= 30 consecutive days, and (iv) hemoglobin A1c >/= 6.5%.

87 g glucose (>/=7.0 mmol/L [>/=126 mg/dL]) and hemoglobin A1c (>/=6.5%) in persons without diagnosed di

88 ferritin, adiponectin, fasting insulin, and hemoglobin A1c (Hb A1c).

89 amperometric method for direct detection of hemoglobin A1c (Hb(A1c)), a potent biomarker for diabete

90 ath Administration Decision Support Services hemoglobin A1c (HbA(c)) and serum glucose data.

91 entral adiposity, stable adiposity, baseline hemoglobin A1c (HbA1c) > 5.05%, HbA1c < 4.92%] and assay

92 glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported physician-di

93 Eating and Living Study were used to measure hemoglobin A1C (HbA1C) among 3,003 survivors of early-st

94 Hemoglobin A1c (HbA1c) and fasting blood glucose levels

95 ay for the dual detection and measurement of hemoglobin A1c (HbA1c) and total hemoglobin in the whole

96 ve of this study is to evaluate the value of hemoglobin A1c (HbA1c) as a screening tool for ketosis i

97 The association of baseline hemoglobin A1c (HbA1c) at the time of percutaneous coron

98 We prospectively evaluated whether hemoglobin A1c (HbA1c) concentrations predict breast can

99 icular blood (GCB) could be used to test for hemoglobin A1c (HbA1c) during periodontal visits.

100 Primary outcome was change in hemoglobin A1c (HbA1c) from baseline to 12-month follow-

101 The primary end point was change in hemoglobin A1c (HbA1c) from baseline to week 26.

102 -14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of Europea

103 Hemoglobin A1C (HbA1C) is associated with increased risk

104 Hemoglobin A1c (HbA1c) is related to glucose metabolism

105 Hemoglobin A1c (HbA1c) is the standard measure to monito

106 of severe hypoglycemic events and maintained hemoglobin A1c (HbA1c) level of </= 6.5%.

107 me to death and longitudinal measurements of hemoglobin A1c (HbA1c) level, after adjustment for all s

108 verse events, myocardial infarction, stroke, hemoglobin A1c (HbA1C) level, treatment failure (rescue

109 revalence and control of diabetes defined by hemoglobin A1c (HbA1c) levels are important for health c

110 Hemoglobin A1c (HbA1c) levels are known to be consistent

111 Hemoglobin A1C (HbA1c) levels are often obtained in pote

112 tudy was to investigate whether preoperative hemoglobin A1c (HbA1c) levels could predict cardiovascul

113 asma insulin levels, insulin resistance, and hemoglobin A1c (HbA1c) levels in first-episode antipsych

114 ise, checking blood glucose levels) and high hemoglobin A1c (HbA1c) levels in patients with diabetes.

115 Debate exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons

116 ls of 12.5 mmol/L or less (</=225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were t

117 ultiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5

118 ng multiple daily insulin injections and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9%.

119 Hemoglobin A1c (HbA1c) levels were also recorded.

120 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels were recorded.

121 or gender, diabetes type, diabetes duration, hemoglobin A1c (HbA1c) levels, and baseline DR severity.

122 Besides lowering glucose and hemoglobin A1c (HbA1c) levels, drug treatment also signi

123 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels, periodontal parameters (p

124 hour glucose level of 200 mg/dL or higher, a hemoglobin A1c (HbA1c) of 6.5% or higher, or diabetes tr

125 5.2 years (range, 0.1-16.2 years) and a mean hemoglobin A1c (HbA1c) of 8.6 (range, 5->/=14).

126 ded 161 individuals with type 1 diabetes and hemoglobin A1c (HbA1c) of at least 7.5% (58 mmol/mol) tr

127 he cause of primary renal allograft failure, hemoglobin A1c (HbA1c) or fasting C-peptide level at ret

128 Whether preoperative hemoglobin A1c (HbA1c) or postoperative glucose levels a

129 Hemoglobin A1c (HbA1c) reflects glycemia over 2-3 months

130 Hemoglobin A1c (HbA1c) reflects past glucose concentrati

131 r than 65 years, the harms associated with a hemoglobin A1c (HbA1c) target lower than 7.5% or higher

132 periodontal examination and a point-of-care hemoglobin A1c (HbA1c) test.

133 ls of fasting plasma glucose (FPG) and blood hemoglobin A1c (HbA1c) than individuals of other genotyp

134 Research targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary hear

135 tic nephropathy group and patients with high hemoglobin A1c (HbA1c) values (>/= 6.5%, >/= 48 mmol/mol

136 ssociation between baseline and time-varying hemoglobin A1c (HbA1c) values and development of communi

137 ams divided by height in meters squared) and hemoglobin A1c (HbA1c) was greater than or equal to 6.5%

138 oprotein [HDL], and triglycerides [TGs]) and hemoglobin A1C (HbA1C) were measured during treatment, w

139 on between duration of diabetes and elevated hemoglobin A1c (HbA1c) with risk of stroke among diabeti

140 ne at week 100 by age, duration of diabetes, hemoglobin A1c (HbA1c), body mass index (BMI), best-corr

141 intervals (CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), to

142 arkers [blood pressure, waist circumference, hemoglobin A1c (HbA1c), insulin resistance, triglyceride

143 fe span is a known determinant of percentage hemoglobin A1c (HbA1c), its variation has been considere

144 Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels,

145 th respect to age, sex, body mass index, and hemoglobin A1C (HbA1C).

146 self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HbA1c).

147 s adjusted using home blood glucose data and hemoglobin A1C (HBA1C).

148 asting blood levels of insulin, glucose, and hemoglobin A1c (HbA1c).

149 s) may be associated with acute decreases in hemoglobin A1c (HbA1c).

150 g levels of glucose, insulin, proinsulin and hemoglobin A1c (HbA1c).

151 Unfortunately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alon

152 rt a potentiometric method for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentratio

153 ith suboptimally controlled type 1 diabetes (hemoglobin A1c [HbA1c] >8.0%) were recruited from the Di

154 (n = 10; 40 +/- 9 years, 8 female subjects, hemoglobin A1c [HbA1c] 7.8 +/- 1.1%) or hyperinsulinemic

155 cantly correlated with DM-related variables (hemoglobin A1c [HbA1c] and fasting glucose) at baseline

156 Intensive glucose control (hemoglobin A1c [HbA1c] level of 7.0) versus moderate glu

157 level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases w

158 Clinical characteristics, glycemic control (hemoglobin A1c [HbA1c]), and presence of diabetic compli

159 s in glycemic control (>/= 0.4% reduction in hemoglobin A1c [HbA1c]), whereas most diabetes self-mana

160 betes mellitus and glycemic status (baseline hemoglobin A1c [HbA1c]: < 6.0% [< 42 mmol/mol], 6.0%-6.4

161 before and after CPB from the UDM patients (hemoglobin A1c [HbA1c]=9.0 +/- 0.3), the CDM patients (H

162 index, high-sensitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and tr

163 hieved stable glycemic control with a median hemoglobin A1C (HgA1C) of 6.9% (range: 5.85%-8.3%).

164 Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were measured; insulin resistanc

165 cted data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, a

166 A second example concerns changes in hemoglobin A1c in a nonrandomized study.

167 correlation between FA of the left ALIC with hemoglobin A1c in diabetic subjects (DC+DD; P=.016).

168 riodontal treatment is associated with lower hemoglobin A1c in individuals with diabetes, but the rel

169 sed by either medical history or an elevated hemoglobin A1c in the ICU.

170 Baseline levels of hemoglobin A1c, inflammatory markers, hemostatic factors

171 id hormone, and, for patients with diabetes, hemoglobin A1c), influenza vaccination, and by at least

172 ocalcin, osteopontin, and serum glycosylated hemoglobin A1c, insulin, and glucose were analyzed in 22

173 mic capillary isoelectric focusing separated hemoglobin A1c into two subfractions identified as A1c1

174 We measured levels of fasting glucose and hemoglobin A1c, intravenous glucose disappearance rates,

175 Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood glucose

176 Eight participants developed diabetes (hemoglobin A1c level >/=6.5%) during the trial: 7 in the

177 vel (-20.2 mg/dL; 95% CI=-39.2 to -1.3), and hemoglobin A1c level (-0.07%; 95% CI=-0.14 to -0.004).

178 They had a favorable effect on hemoglobin A1c level (mean difference vs. placebo, -0.66

179 Change in hemoglobin A1c level (primary outcome) and safety and ef

180 ith interstitial macrophage infiltration and hemoglobin A1c level and inversely with estimated glomer

181 th T2DM-related clinical measures, including hemoglobin A1c level and vascular risk factors, and neur

182 atment as predictor and the actual change in hemoglobin A1c level as the outcome.

183 In a meta-analysis, hemoglobin A1c level decreased by 0.4% (95% CI, 0.1% to

184 pe 2 diabetes, there was a small decrease in hemoglobin A1c level from baseline that favored subcutan

185 A hemoglobin A1c level less than 7% based on individualize

186 Diabetes was defined as hemoglobin A1c level of >/=6.5%, use of diabetic medicat

187 ucose level of 410 mg/dL (22.8 mmol/L) and a hemoglobin A1C level of 18.0%.

188 Prediabetes was defined as a hemoglobin A1c level of 5.7% to 6.4%, an FPG level of 10

189 betes was not previously diagnosed, by (1) a hemoglobin A1c level of 6.5% or greater or a fasting pla

190 owest DNT quartile (score <42%) had a median hemoglobin A1c level of 7.6% (interquartile range, 6.5%

191 nd 18.5% had type 1 diabetes and a mean (SD) hemoglobin A1C level of 7.7% (1.8) (n = 27).

192 hemoglobin A1c, equivalent to a reduction in hemoglobin A1c level of about 0.81%.

193 egree as sulfonylureas (absolute decrease in hemoglobin A1c level of about 1 percentage point).

194 The goal for hemoglobin A1c level should be based on individualized a

195 The mean (SD) hemoglobin A1c level was 7.8% (2.4%) (to convert to prop

196 n for a median of 14 months (IQR, 5-30), and hemoglobin A1c level was 8.1% (IQR, 7.2%-9.9%).

197 Hemoglobin A1c level was not associated with any MR imag

198 nsulin improved overall glycemic control and hemoglobin A1c level when added to or substituted for du

199 controlled diabetes (from 12.7% to 47.6% if hemoglobin A1c level>/=9%), use of antipsychotics (from

200 py, accompanied with a subsequently recorded hemoglobin A1c level<6.0%).

201 Mean (SD) age was 47.3 (6.4) years and hemoglobin A1c level, 7.9% (2.0%).

202 t, 47.3 (6.6) years for age, 7.8% (1.9%) for hemoglobin A1c level, and 171.3 (72.5) mg/dL for fasting

203 adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we found that n

204 After adjustment for sex, age, hemoglobin A1c level, and retinopathy level at DCCT base

205 ore (ie, blood pressure, waist to hip ratio, hemoglobin A1c level, and the ratio of apolipoprotein B

206 ype 2 diabetes and established risk factors (hemoglobin A1c level, body mass index, waist-height rati

207 emographics, medications, cholesterol level, hemoglobin A1c level, creatinine level, blood pressure,

208 , body mass index, C-reactive protein level, hemoglobin A1c level, phosphorus level, troponin T level

209 d 8 processes of care, including most recent hemoglobin A1c level, systolic blood pressure, serum low

210 d a modest association between DNT score and hemoglobin A1c level.

211 rate, plasminogen activator inhibitor-1, and hemoglobin A1c level.

212 Baseline descriptive data, hemoglobin A1c (%) level, time since diagnosis of T1DM (

213 in (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, body mass i

214 +/- 14 mg/dL vs 8 +/- 17 mg/dL [P < .001]), hemoglobin A1c levels (26 weeks: 0.1 +/- 0.3% vs 0.3 +/-

215 ntation resulted in a remarkable decrease in hemoglobin A1c levels (7.4+/-1.9 pre-LVAD versus 6.0+/-1

216 tion was associated with significantly lower hemoglobin A1c levels (beta = -0.37; 95% CI, -0.72 to -0

217 amcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%;

218 Patients with higher hemoglobin A1c levels (OR, 1.19 per unit change; 95% CI,

219 Lower hemoglobin A1c levels (P < 0.01), having insurance (P =

220 -stratified blood pressure, cholesterol, and hemoglobin A1c levels and treatment and control rates in

221 gain, and worsening diabetic retinopathy if hemoglobin A1C levels decrease rapidly.

222 bjects with high depression ratings and high hemoglobin A1c levels had the lowest mean FA values in t

223 n = 54) and after adjustment for covariates, hemoglobin A1c levels improved more for persons on the l

224 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.5%] in th

225 tage of participants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma g

226 in the proportion of participants achieving hemoglobin A1c levels less than 7%.

227 Inhaled insulin lowered hemoglobin A1c levels more (weighted mean difference fav

228 s index and triglyceride, blood glucose, and hemoglobin A1c levels sharply decreased during the first

229 At baseline, mean (+/-SD) hemoglobin A1c levels were 7.28% +/- 1.43%; follow-up va

230 Hemoglobin A1c levels were ordered at all ICU admissions

231 ody mass index, duration posttransplant, and hemoglobin A1c levels were similar between groups.

232 e physicians' and patients' ability to lower hemoglobin A1C levels with fewer episodes of hypoglycemi

233 l glycosylated hemoglobin, hemoglobin A1, or hemoglobin A1c levels) and cardiovascular disease events

234 ntrol (range, 0.9-1.43 point improvements in hemoglobin A1c levels) during 1 to 2 years of follow-up

235 ssure), measures of diabetes status (such as hemoglobin A1c levels), and quality of life.

236 k factors for CVD, inflammatory markers, and hemoglobin A1c levels).

237 ed by testing fasting plasma glucose levels, hemoglobin A1c levels, and duration of diabetes.

238 lucose levels, oral glucose tolerance tests, hemoglobin A1C levels, and/or antidiabetic medications.

239 o short-term effect on secondary outcomes of hemoglobin A1c levels, depression, or the Risk Perceptio

240 dults, undiagnosed adults have less elevated hemoglobin A1c levels, less lipid treatment and worse co

241 lycerides, homocysteine, C-reactive protein, hemoglobin A1c levels, serum creatinine, mean blood pres

242 Vision Function Questionnaire 25 scores and hemoglobin A1c levels.

243 (with the exception of interleukin 22) with hemoglobin A1c levels.

244 achieved, as determined by blood glucose and hemoglobin A1c levels.

245 diabetics with poor glucose control and high hemoglobin A1c levels.

246 ening, foot examinations, and measurement of hemoglobin A1c levels.

247 ory of diabetes), controlled known diabetes (hemoglobin A1c < 6.5%, with documented history of diabet

248 , without history of diabetes), no diabetes (hemoglobin A1c < 6.5%, without history of diabetes), con

249 ts of intensive and standard treatment were: hemoglobin A1c <6.0% and 7.0% to 7.9%, respectively, and

250 Rate of remission of T2DM (hemoglobin A1C <6.0% without antiglycemic medication) wa

251 litus and prediabetes was estimated based on hemoglobin A1c measurements.

252 An increase in hemoglobin A1c of 1 percentage point was associated with

253 to insulin was associated with a decrease in hemoglobin A1c of approximately 1.0%.

254 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 24 women;

255 ated with higher random C-peptide were lower hemoglobin A1C, older age of onset, higher frequency of

256 Further adjustment for hemoglobin A1c or C-reactive protein levels also had lit

257 density or foveal avascular zone metrics and hemoglobin A1C or duration of diabetes.

258 ized prevalence of total diabetes (using the hemoglobin A1c or FPG definition) increased from 9.8% (9

259 glucose (FPG) level of 126 mg/dL or greater (hemoglobin A1c or FPG definition) or (2) additionally in

260 sted prevalence of total diabetes (using the hemoglobin A1c or FPG definition) was 12.3% (95% CI, 10.

261 95% CI, 1.07-1.11 per year increase), higher hemoglobin A1c (OR, 1.23; 95% CI, 1.13-1.34 per percent

262 Elevated levels of glycosylated hemoglobin A1c (OR, 1.47; 95% CI, 1.26-1.71 for each 1%;

263 iated with benefits (measured by lowering of hemoglobin A1c) or adverse effects?

264 easures (for example, 93% vs. 83% for annual hemoglobin A1c; P = 0.006; 91% vs. 75% for annual eye ex

265 f baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selection bias

266 The only significant predictor of glycated hemoglobin A1c reduction was waist circumference, lower

267 Hemoglobin A1C should be measured every 3 months and the

268 Empagliflozin reduced hemoglobin A1c significantly in both groups, despite low

269 duration of diabetes mellitus, glycosylated hemoglobin A1c, statin use, and end-stage renal disease.

270 Hemoglobin A1c stratified by the presence or absence of

271 ively and significantly associated with BMI, hemoglobin A1c, systolic blood pressure, total cholester

272 The hemoglobin A1c target for most patients with type 2 diab

273 shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment p

274 xamination (OR = 1.49; CI, 1.28-1.74), prior hemoglobin A1c test (OR = 1.45; CI, 1.28-1.64), and havi

275 of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the pair of events identi

276 ge points per measure): eye examinations and hemoglobin A1c testing for patients with diabetes, chlam

277 -adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mellitus coul

278 ease between 2006 and 2010, but increases in hemoglobin A1c testing may have contributed to rising di

279 cators: disease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein chol

280 cators: disease monitoring (eye examination, hemoglobin A1c testing, and low-density lipoprotein chol

281 glucose test (55% effectiveness; $498), or a hemoglobin A1c threshold of 5.5% (45% effectiveness; $76

282 Hemoglobin A1c thresholds of 5.7% and 6.5% were the leas

283 traits, including increased fasting glucose, hemoglobin A1C, total and LDL cholesterol, triglycerides

284 ealthy women, we measured baseline levels of hemoglobin A1c, traditional lipids (total, low-density l

285 DM had higher mean (SD) preoperative BMI and hemoglobin A1C values (39.4 [8.5] and 8.7% [3.8%] of tot

286 Prediabetes was defined as follows: 1) hemoglobin A1c values ranging from 5.7% to 6.4% or 2) fa

287 Reductions in hemoglobin A1c values were similar across monotherapies

288 ss, self-efficacy, medication adherence, and hemoglobin A1c values.

289 29.7 (interquartile range 25.5-35.3), median hemoglobin A1c was 6.8 (interquartile range 6.2-7.8), an

290 in nondiabetic individuals, a 1% increase in hemoglobin A1c was associated with greater AD signature

291 Specifically, in diabetics, higher levels of hemoglobin A1c was associated with greater risk for 4-ye

292 Preoperative hemoglobin A1c was not significantly associated with mor

293 dds ratio, 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatme

294 ts relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (co

295 d outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and hea

296 Reductions in fasting glucose levels and hemoglobin A1c were greater after distal gastric bypass.

297 whereas total body fat mass, VAT, SSAT, and hemoglobin A1c were reduced comparably in both intervent

298 At 3 years, median serum creatinine and hemoglobin A1C were similar between the induction and no

299 Associations of BP and hemoglobin A1c with change in eGFR were strongest for eG

300 ctions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability.